What is Complement 1?
Founded in 2024 and headquartered in the United States, Complement 1 operates within the dynamic healthcare industry. The company specializes in a clinically validated, AI-driven lifestyle modification platform designed for cancer patients, survivors, and individuals at high risk. Its core offering is a personalized program that integrates daily coaching from certified CoActive Coaches with evidence-based interventions in nutrition, physical activity, and mind-body practices. Clinical trials have substantiated the platform's efficacy, demonstrating notable improvements in patient outcomes, including the mitigation of treatment side effects and an overall enhancement in quality of life.
How much funding has Complement 1 raised?
Complement 1 has raised a total of $16M across 1 funding round:
Seed
$16M
Seed (2025): $16M with participation from Owl Ventures and Blume Ventures
Key Investors in Complement 1
Owl Ventures
Owl Ventures is a global leader in education technology investing, focusing on innovative solutions that enhance learning experiences. The company supports a diverse range of edtech companies, including those providing tools for personalized tutoring, virtual classrooms, and workforce upskilling. With a deep understanding of the K-12 space and a strong network, Owl Ventures plays a crucial role in scaling its portfolio companies globally. Their commitment to democratizing access to quality education drives their investment philosophy and partnership approach.
Blume Ventures
Blume Ventures is an India focused early stage investment firm that backs founders from seed through scale up. With local insight and hands on support, it partners with teams building enduring technology led businesses across consumer, enterprise and deep tech, helping them raise capital, sharpen strategy and grow responsibly.
What's next for Complement 1?
With the infusion of major enterprise-level capital, Complement 1 is strategically positioned for significant expansion and further development of its AI-driven platform. This substantial backing, particularly the recent strategic investment, signals an intent to scale operations, enhance its coaching network, and potentially broaden its market reach. The company's focus on evidence-based interventions and measurable patient outcomes suggests a trajectory aimed at solidifying its position as a leader in personalized oncology support, likely exploring further clinical validation and strategic partnerships to drive adoption across healthcare systems.
See full Complement 1 company page
